PTEN and nasopharyngeal carcinoma: Data obtained from mouse models in preclinical studies indicate that weekly administration is effective for the treatment of AML, which supports its use in subsequent clinical trials.212 A preclinical study on the inhibitor MK-2206 in nasopharyngeal carcinoma (NPC) is also ongoing.213 HGF was used to resensitize drug-resistant cells to the drug, revealing the therapeutic efficacy of MK-2206.211 The efficacy of MK-2206 was also reported in a phase I clinical trial in which the tumors of patients with PTEN-deficient pancreatic cancer regressed after treatment with MK-2206 alone.